in each of these patients. The peak plasma ara-C level was ten to 30 times higher than the mean plasma ara-C level achieved during the continuous infusion schedule in the same patient.
At three hours after bolus injection, the plasma ara-C level had fallen below the mean plasma ara-C level achieved by continuous infusion. There was no detectable ara-C present in plasma at six hours after bolus injection.
The AUC as determined by the trapezoid rule was 532 nmol/L x hour for patient 1 (Fig 2A) and 1,044 nmol/L x hour for patient 5 ( Fig  2B) . The AUC for 12-hour continuous IV infusions calculated from the mean plasma ara-C level was 771 nmol/L x hour for patient I and 630 nmol/L x hour for patient 5. Thus, the total drug exposure was similar when the bolus SC or continuous IV infusion regimen was used.
DISCUSSION
Low-dose ara-C regimens have had varying success in the treatment of preleukemia and acute leukemia.
Several studies using 10 to 20 mg/m2 ara-C as a bolus injection every 1 2 hours have had generally disappointing results.'#{176}" 8 These studies utilized a twice-daily 
